abstract：:Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

journal_title：Drugs

authors： Scott LJ,Keam SJ

更新日期：2021-01-06 00:00:00

abstract：:Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of < 1% in solid tumors. Detection of TRK fusions can be based on fluorescence in-si...

journal_title：Drugs

authors： Rohrberg KS,Lassen U

更新日期：2021-01-05 00:00:00

abstract：:Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

journal_title：Drugs

authors： Syed YY

更新日期：2021-01-01 00:00:00

abstract：:Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity, registration trials of immunotherapy in prostate cancer have largely been unsuccessful. Sipuleucel-T remains the only approved immunotherapy for the treatment of asymptomatic or m...

journal_title：Drugs

authors： Rathi N,McFarland TR,Nussenzveig R,Agarwal N,Swami U

更新日期：2020-12-28 00:00:00

abstract：INTRODUCTION:Several pharmacological treatments aiming at a better symptomatic control of osteoarthritis (OA) are used in daily practice but their efficacy is often disputed. The purpose of this network meta-analysis (NMA) is to assess the efficacy on pain and function of the drugs that are most widely prescribed again...

journal_title：Drugs

authors： Beaudart C,Lengelé L,Leclercq V,Geerinck A,Sanchez-Rodriguez D,Bruyère O,Reginster JY

更新日期：2020-12-01 00:00:00

abstract：:Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

journal_title：Drugs

authors： Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

更新日期：2020-11-28 00:00:00

abstract：:Chronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. C...

journal_title：Drugs

authors： Giménez-Arnau AM,Salman A

更新日期：2020-11-01 00:00:00

abstract：:Approximately 70% of invasive breast cancers have some degree of dependence on the estrogen hormone for cell proliferation and growth. These tumors have estrogen and/or progesterone receptors (ER/PR+), generally referred to as hormone receptor positive (HR+) tumors, as indicated by the presence of positive staining an...

journal_title：Drugs

authors： Nunnery SE,Mayer IA

更新日期：2020-11-01 00:00:00

abstract：:Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

journal_title：Drugs

authors： Dhillon S

更新日期：2020-11-01 00:00:00

abstract：:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...

journal_title：Drugs

authors： Hajra A,Mathai SV,Ball S,Bandyopadhyay D,Veyseh M,Chakraborty S,Lavie CJ,Aronow WS

更新日期：2020-10-01 00:00:00

abstract：:Page 9, Fig. 2, which originally appeared as. ...

journal_title：Drugs

authors： Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

更新日期：2020-10-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-09-01 00:00:00

abstract：:Pain is associated with emotional and physical suffering that severely impacts quality of life. Many guidelines for the treatment of moderate to severe cancer pain indicate the use of opioids. For a small proportion of the global population, opioids are readily accessible, but are consequently also subject to risk of ...

journal_title：Drugs

authors： Marchetti Calônego MA,Sikandar S,Ferris FD,Moreira de Barros GA

更新日期：2020-08-01 00:00:00

abstract：:Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...

journal_title：Drugs

authors： Kichler A,Jang S

更新日期：2020-08-01 00:00:00

abstract：:Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that transduces signals from cell surface cytokine and growth factor receptors to the nucleus. Recently developed JAK inhibitors (JAKinibs) inhibit JAKs non-selectively or selectively and down-regulate the effects of correspondin...

journal_title：Drugs

authors： Harigai M,Honda S

更新日期：2020-08-01 00:00:00

abstract：:Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...

journal_title：Drugs

authors： Syed YY

更新日期：2020-07-01 00:00:00

abstract：:Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...

journal_title：Drugs

authors： Somasundaram A,Socinski MA,Villaruz LC

更新日期：2020-06-01 00:00:00

abstract：:In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

journal_title：Drugs

authors： Dhillon S

更新日期：2020-06-01 00:00:00

abstract：:Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

journal_title：Drugs

authors： Pourang A,Mesinkovska NA

更新日期：2020-05-01 00:00:00

abstract：:Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...

journal_title：Drugs

authors： Deeks ED,Lamb YN

更新日期：2020-04-01 00:00:00

abstract：:Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-03-01 00:00:00

abstract：:Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...

journal_title：Drugs

authors： Dhillon S

更新日期：2020-03-01 00:00:00

abstract：:The original article has been corrected. ...

journal_title：Drugs

authors： Lamb YN

更新日期：2020-03-01 00:00:00

abstract：:Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-02-01 00:00:00

abstract：:Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

journal_title：Drugs

authors： Keam SJ

更新日期：2020-01-01 00:00:00

abstract：:Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be shown that immunotherapy works as consolidation after chemoradiotherapy in locally adv...

journal_title：Drugs

authors： Heigener DF,Reck M

更新日期：2019-12-01 00:00:00

abstract：:Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

journal_title：Drugs

authors： Deeks ED

更新日期：2019-12-01 00:00:00

abstract：:Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains ...

journal_title：Drugs

authors： Lukas RV,Wainwright DA,Horbinski CM,Iwamoto FM,Sonabend AM

更新日期：2019-11-01 00:00:00

abstract：:The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...

journal_title：Drugs

authors： Markham A

更新日期：2019-11-01 00:00:00

abstract：:The article Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer, written by Connie Kang, Sohita Dhillon and Emma D. Deeks, was originally published Online First without open access. ...

journal_title：Drugs

authors： Kang C,Dhillon S,Deeks ED

更新日期：2019-10-01 00:00:00

abstract：:Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...

journal_title：Drugs

authors： Blair HA

更新日期：2019-10-01 00:00:00

abstract：:An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including ...

journal_title：Drugs

authors： Hoy SM

更新日期：2019-10-01 00:00:00

abstract：:Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an important cause of morbidity and mortality. The management of connective tissue disease-interstitial lung disease (CTD-ILD) is challenging due substantial heterogeneity in disease behaviour and paucity of controlled clinica...

journal_title：Drugs

authors： Jee AS,Corte TJ

更新日期：2019-09-01 00:00:00

abstract：:ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...

journal_title：Drugs

authors： Morris TA,Khoo C,Solomon BJ

更新日期：2019-08-01 00:00:00

abstract：:Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...

journal_title：Drugs

authors： Schehlein EM,Robin AL

更新日期：2019-07-01 00:00:00

abstract：:Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...

journal_title：Drugs

authors： Raterman HG,Bultink IEM,Lems WF

更新日期：2019-07-01 00:00:00

abstract：:Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

journal_title：Drugs

authors： Paik J,Deeks ED

更新日期：2019-07-01 00:00:00

abstract：:Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

journal_title：Drugs

authors： Markham A,Keam SJ

更新日期：2019-06-01 00:00:00

abstract：:Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...

journal_title：Drugs

authors： Blanton HL,Brelsfoard J,DeTurk N,Pruitt K,Narasimhan M,Morgan DJ,Guindon J

更新日期：2019-06-01 00:00:00

abstract：:Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different...

journal_title：Drugs

authors： Torti M,Bravi D,Vacca L,Stocchi F

更新日期：2019-05-01 00:00:00